Skip to main content
. 2006 Sep 28;65(12):1572–1577. doi: 10.1136/ard.2006.056747

graphic file with name ar56747.f2.jpg

Figure 2 Assessment in Ankylosing Spondylitis responders (%) over time (modified intent‐to‐treat population; last‐observation‐carried‐forward approach). (A) ASAS 20; (B) ASAS 5/6; (C) ASAS 40. BIW, twice weekly; QW, once weekly. *p<0.05, etanercept 50 mg QW versus placebo. †p<0.05, etanercept 25 mg BIW versus placebo.